The post-traumatic stress disorder therapeutics market size has grown steadily in recent years. It will grow from $1.2 billion in 2025 to $1.23 billion in 2026 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to increased prevalence of ptsd, growing awareness of mental health, limited availability of specialized therapists, reliance on traditional pharmacological treatments, rising incidence of trauma from conflicts and disasters.
The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.41 billion in 2030 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to advancement in ai-driven diagnostics, expansion of telehealth platforms, growth in precision medicine solutions, adoption of wearable health monitoring, increasing investment in holistic mental health therapies. Major trends in the forecast period include personalized ptsd treatment plans, teletherapy & remote mental health services, integration of nutritional interventions in ptsd care, non-pharmacological therapy adoption, wearable monitoring devices for stress management.
The increasing global burden of post-traumatic stress disorder (PTSD) cases is expected to drive the growth of the PTSD therapeutics market in the coming years. PTSD is a disorder that develops in individuals who have experienced or witnessed a traumatic, shocking, or dangerous event. Treatments like psychotherapy and medication help individuals regain control over their lives. For example, in March 2024, the Ministry of Defence (MoD) Department of Community Mental Health (DCMH), a UK-based organization providing mental health services to armed forces personnel and reservists, reported a significant increase in the number of PTSD cases. The number of armed forces personnel receiving initial PTSD assessments by a specialist mental health clinician rose from 266 cases in 2022 to 320 cases in 2023. This surge in reported PTSD cases is contributing to the growth of the PTSD therapeutics market.
Major companies in the PTSD therapeutics market are focusing on developing advanced technological devices, such as self-neuromodulation devices, to enhance patient outcomes and offer alternatives to traditional therapies. Self-neuromodulation devices aim to improve PTSD treatment by combining computer simulations with EEG technology. This allows patients to regulate amygdala activity, which is associated with the hyperactivity often seen in PTSD, and provides complementary therapy alongside conventional treatments. For example, in January 2024, GrayMatters Health, a U.S.-based health technology company, launched Prism for PTSD, the first FDA-approved self-neuromodulation device designed to treat PTSD in the U.S. The device uses a combination of computer simulations and an EEG headset to create an immersive environment, helping individuals regulate amygdala-based biomarker activity linked to PTSD. The technology behind Prism for PTSD is the digital EEG-fMRI-Pattern (EFP) biomarker, which tracks brain-area-specific activity by synchronizing fMRI amygdala data with EEG readings. This therapy targets the amygdala, which research has shown to be hyperactive in individuals with PTSD.
In June 2023, Stella Center, a U.S.-based provider of PTSD treatment, acquired the U.S. assets of Field Trip Health for an undisclosed amount. This acquisition broadens Stella’s range of advanced treatments and includes Field Trip’s outcome data, research, technology stack, clinics, and leadership. Field Trip Health, a Canada-based provider of psychedelic-assisted therapies for mental health conditions like PTSD, strengthens Stella's position in the PTSD therapeutics market.
Major companies operating in the post-traumatic stress disorder therapeutics market are Pfizer Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, AstraZeneca plc, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Halucenex Life Sciences Inc., MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Compass Pathways plc, Alkermes plc, MindMed Inc., Atai Life Sciences, Karuna Therapeutics, Mindbloom Inc.
North America was the largest region in the post-traumatic stress disorder therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-traumatic stress disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the post-traumatic stress disorder therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized therapy equipment, particularly affecting segments such as antidepressants, antipsychotics, and wearable monitoring devices. Regions like North America and Europe, which rely on global imports, have faced higher production costs and supply delays. While challenging, tariffs have encouraged local manufacturing and sourcing, stimulating domestic innovation and cost-optimized PTSD therapeutic solutions.
The post-traumatic stress disorder therapeutics market research report is one of a series of new reports that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed post-traumatic stress disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This post-traumatic stress disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Post-traumatic stress disorder (PTSD) therapeutics refers to treatments used to address PTSD, a mental health condition that arises from experiencing or witnessing traumatic events. These treatments aim to improve patients' cognitive abilities, physical activity, and help them regain control over their lives. The modes of treatment for PTSD include medications, therapies, self-care practices, and nutritional support.
The main drugs used in PTSD therapeutics include antidepressants, anti-anxiety medications, antihypertensive drugs, monoamine oxidase inhibitors (MAOIs), antipsychotics (including second-generation antipsychotics, or SGAs), beta-blockers, and other medications such as benzodiazepines. Antidepressants are a class of drugs commonly used to manage depression, anxiety disorders, addictions, and chronic pain. PTSD therapeutics are prescribed to various age groups, including pediatric, adult, and geriatric patients. These treatments are provided through different healthcare settings, such as mental health centers, hospitals, outpatient clinics, and others.
The post-traumatic stress disorder therapeutics market consists of revenues earned by entities by providing treatment services such as psychotherapy, medication, and the combination. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-traumatic stress disorder therapeutics market also includes sales of drugs including Sertraline, Paroxetine, and Fluoxetine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The post-traumatic stress disorder therapeutics market size is expected to see steady growth in the next few years. It will grow to $1.41 billion in 2030 at a compound annual growth rate (CAGR) of 3.4%. The growth in the forecast period can be attributed to advancement in ai-driven diagnostics, expansion of telehealth platforms, growth in precision medicine solutions, adoption of wearable health monitoring, increasing investment in holistic mental health therapies. Major trends in the forecast period include personalized ptsd treatment plans, teletherapy & remote mental health services, integration of nutritional interventions in ptsd care, non-pharmacological therapy adoption, wearable monitoring devices for stress management.
The increasing global burden of post-traumatic stress disorder (PTSD) cases is expected to drive the growth of the PTSD therapeutics market in the coming years. PTSD is a disorder that develops in individuals who have experienced or witnessed a traumatic, shocking, or dangerous event. Treatments like psychotherapy and medication help individuals regain control over their lives. For example, in March 2024, the Ministry of Defence (MoD) Department of Community Mental Health (DCMH), a UK-based organization providing mental health services to armed forces personnel and reservists, reported a significant increase in the number of PTSD cases. The number of armed forces personnel receiving initial PTSD assessments by a specialist mental health clinician rose from 266 cases in 2022 to 320 cases in 2023. This surge in reported PTSD cases is contributing to the growth of the PTSD therapeutics market.
Major companies in the PTSD therapeutics market are focusing on developing advanced technological devices, such as self-neuromodulation devices, to enhance patient outcomes and offer alternatives to traditional therapies. Self-neuromodulation devices aim to improve PTSD treatment by combining computer simulations with EEG technology. This allows patients to regulate amygdala activity, which is associated with the hyperactivity often seen in PTSD, and provides complementary therapy alongside conventional treatments. For example, in January 2024, GrayMatters Health, a U.S.-based health technology company, launched Prism for PTSD, the first FDA-approved self-neuromodulation device designed to treat PTSD in the U.S. The device uses a combination of computer simulations and an EEG headset to create an immersive environment, helping individuals regulate amygdala-based biomarker activity linked to PTSD. The technology behind Prism for PTSD is the digital EEG-fMRI-Pattern (EFP) biomarker, which tracks brain-area-specific activity by synchronizing fMRI amygdala data with EEG readings. This therapy targets the amygdala, which research has shown to be hyperactive in individuals with PTSD.
In June 2023, Stella Center, a U.S.-based provider of PTSD treatment, acquired the U.S. assets of Field Trip Health for an undisclosed amount. This acquisition broadens Stella’s range of advanced treatments and includes Field Trip’s outcome data, research, technology stack, clinics, and leadership. Field Trip Health, a Canada-based provider of psychedelic-assisted therapies for mental health conditions like PTSD, strengthens Stella's position in the PTSD therapeutics market.
Major companies operating in the post-traumatic stress disorder therapeutics market are Pfizer Inc., GlaxoSmithKline plc, Otsuka Pharmaceutical Co Ltd., Eli Lilly and Company, AstraZeneca plc, Tonix Pharmaceuticals Holding Corp., Freespira Inc., MicroTransponder Inc., Halucenex Life Sciences Inc., MAPS Europe BV, Hoffmann-La Roche Ltd., Praxis Precision Medicines Inc., H Lundbeck A/S, Johnson & Johnson, Sanofi SA, Compass Pathways plc, Alkermes plc, MindMed Inc., Atai Life Sciences, Karuna Therapeutics, Mindbloom Inc.
North America was the largest region in the post-traumatic stress disorder therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the post-traumatic stress disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the post-traumatic stress disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the post-traumatic stress disorder therapeutics market by increasing the cost of imported active pharmaceutical ingredients (APIs) and specialized therapy equipment, particularly affecting segments such as antidepressants, antipsychotics, and wearable monitoring devices. Regions like North America and Europe, which rely on global imports, have faced higher production costs and supply delays. While challenging, tariffs have encouraged local manufacturing and sourcing, stimulating domestic innovation and cost-optimized PTSD therapeutic solutions.
The post-traumatic stress disorder therapeutics market research report is one of a series of new reports that provides post-traumatic stress disorder therapeutics market statistics, including post-traumatic stress disorder therapeutics industry global market size, regional shares, competitors with a post-traumatic stress disorder therapeutics market share, detailed post-traumatic stress disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the post-traumatic stress disorder therapeutics industry. This post-traumatic stress disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Post-traumatic stress disorder (PTSD) therapeutics refers to treatments used to address PTSD, a mental health condition that arises from experiencing or witnessing traumatic events. These treatments aim to improve patients' cognitive abilities, physical activity, and help them regain control over their lives. The modes of treatment for PTSD include medications, therapies, self-care practices, and nutritional support.
The main drugs used in PTSD therapeutics include antidepressants, anti-anxiety medications, antihypertensive drugs, monoamine oxidase inhibitors (MAOIs), antipsychotics (including second-generation antipsychotics, or SGAs), beta-blockers, and other medications such as benzodiazepines. Antidepressants are a class of drugs commonly used to manage depression, anxiety disorders, addictions, and chronic pain. PTSD therapeutics are prescribed to various age groups, including pediatric, adult, and geriatric patients. These treatments are provided through different healthcare settings, such as mental health centers, hospitals, outpatient clinics, and others.
The post-traumatic stress disorder therapeutics market consists of revenues earned by entities by providing treatment services such as psychotherapy, medication, and the combination. The market value includes the value of related goods sold by the service provider or included within the service offering. The post-traumatic stress disorder therapeutics market also includes sales of drugs including Sertraline, Paroxetine, and Fluoxetine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Post-Traumatic Stress Disorder Therapeutics Market Characteristics
3. Post-Traumatic Stress Disorder Therapeutics Market Supply Chain Analysis
4. Global Post-Traumatic Stress Disorder Therapeutics Market Trends and Strategies
5. Post-Traumatic Stress Disorder Therapeutics Market Analysis of End Use Industries
7. Global Post-Traumatic Stress Disorder Therapeutics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Post-Traumatic Stress Disorder Therapeutics Total Addressable Market (TAM) Analysis for the Market
9. Post-Traumatic Stress Disorder Therapeutics Market Segmentation
10. Post-Traumatic Stress Disorder Therapeutics Market Regional and Country Analysis
11. Asia-Pacific Post-Traumatic Stress Disorder Therapeutics Market
12. China Post-Traumatic Stress Disorder Therapeutics Market
13. India Post-Traumatic Stress Disorder Therapeutics Market
14. Japan Post-Traumatic Stress Disorder Therapeutics Market
15. Australia Post-Traumatic Stress Disorder Therapeutics Market
16. Indonesia Post-Traumatic Stress Disorder Therapeutics Market
17. South Korea Post-Traumatic Stress Disorder Therapeutics Market
18. Taiwan Post-Traumatic Stress Disorder Therapeutics Market
19. South East Asia Post-Traumatic Stress Disorder Therapeutics Market
20. Western Europe Post-Traumatic Stress Disorder Therapeutics Market
21. UK Post-Traumatic Stress Disorder Therapeutics Market
22. Germany Post-Traumatic Stress Disorder Therapeutics Market
23. France Post-Traumatic Stress Disorder Therapeutics Market
24. Italy Post-Traumatic Stress Disorder Therapeutics Market
25. Spain Post-Traumatic Stress Disorder Therapeutics Market
26. Eastern Europe Post-Traumatic Stress Disorder Therapeutics Market
27. Russia Post-Traumatic Stress Disorder Therapeutics Market
28. North America Post-Traumatic Stress Disorder Therapeutics Market
29. USA Post-Traumatic Stress Disorder Therapeutics Market
30. Canada Post-Traumatic Stress Disorder Therapeutics Market
31. South America Post-Traumatic Stress Disorder Therapeutics Market
32. Brazil Post-Traumatic Stress Disorder Therapeutics Market
33. Middle East Post-Traumatic Stress Disorder Therapeutics Market
34. Africa Post-Traumatic Stress Disorder Therapeutics Market
36. Post-Traumatic Stress Disorder Therapeutics Market Competitive Landscape and Company Profiles
37. Post-Traumatic Stress Disorder Therapeutics Market Other Major and Innovative Companies
40. Post-Traumatic Stress Disorder Therapeutics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Post-Traumatic Stress Disorder Therapeutics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses post-traumatic stress disorder therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for post-traumatic stress disorder therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The post-traumatic stress disorder therapeutics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Drug Class: Antidepressants; Anti-Anxiety; Antihypertensive; Antipsychotics Or Second Generation Antipsychotics (SGOs); Beta-Blockers; Other Classes2) By Age Group: Pediatric; Geriatric; Adult
3) By End User: Mental Health Center; Hospitals; Outpatient Clinics; Other End Users
Subsegments:
1) By Antidepressants: Selective Serotonin Reuptake Inhibitors (SSRIs); Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)2) By Anti-Anxiety: Benzodiazepines; Buspirone
3) By Antihypertensive: Prazosin; Clonidine
4) By Antipsychotics (Second Generation Antipsychotics - SGOs): Risperidone; Quetiapine
5) By Beta-Blockers: Propranolol; Atenolol
6) By Other Classes: Mood Stabilizers; Adjunctive Therapies
Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; Otsuka Pharmaceutical Co Ltd.; Eli Lilly and Company; AstraZeneca plc; Tonix Pharmaceuticals Holding Corp.; Freespira Inc.; MicroTransponder Inc.; Halucenex Life Sciences Inc.; MAPS Europe BV; Hoffmann-La Roche Ltd.; Praxis Precision Medicines Inc.; H Lundbeck A/S; Johnson & Johnson; Sanofi SA; Compass Pathways plc; Alkermes plc; MindMed Inc.; Atai Life Sciences; Karuna Therapeutics; Mindbloom Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Post-Traumatic Stress Disorder Therapeutics market report include:- Pfizer Inc.
- GlaxoSmithKline plc
- Otsuka Pharmaceutical Co Ltd.
- Eli Lilly and Company
- AstraZeneca plc
- Tonix Pharmaceuticals Holding Corp.
- Freespira Inc.
- MicroTransponder Inc.
- Halucenex Life Sciences Inc.
- MAPS Europe BV
- Hoffmann-La Roche Ltd.
- Praxis Precision Medicines Inc.
- H Lundbeck A/S
- Johnson & Johnson
- Sanofi SA
- Compass Pathways plc
- Alkermes plc
- MindMed Inc.
- Atai Life Sciences
- Karuna Therapeutics
- Mindbloom Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.23 Billion |
| Forecasted Market Value ( USD | $ 1.41 Billion |
| Compound Annual Growth Rate | 3.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
